title: N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial.
abstract: OBJECTIVE
  To evaluate oral N-acetylcysteine in the prevention of contrast induced nephropathy (CIN) in patients at low to moderate risk undergoing cardiac catheterisation with ionic low osmolality contrast medium.
  
  
  METHODS
  In a multicentre double blind clinical trial 156 patients undergoing coronary angiography or percutaneous coronary intervention with serum creatinine > or = 106.08 micromol/l or creatinine clearance < 50 ml/min or diabetes mellitus were randomly assigned to receive N-acetylcysteine 600 mg orally twice daily for two days or placebo. Only low osmolality ionic contrast medium was used.
  
  
  RESULTS
  Sixteen patients developed CIN, defined as an increase of 44.2 micromol/l in creatinine in 48 hours: eight of 77 patients (10.4%) in the N-acetylcysteine group and eight of 79 patients (10.1%) in the placebo group (p = 1.00). The mean (SD) change in serum creatinine was similar in both groups: 7.96 (35.36) micromol/l in the N-acetylcysteine group and 6.19 (25.64) micromol/l in the placebo group (p = 0.67). No difference was observed in the change in endogenous creatinine clearance (-0.54 (10.4) ml/min v -2.52 (12.3) ml/min, N-acetylcysteine and placebo, respectively, p = 0.28).
  
  
  CONCLUSIONS
  Oral N-acetylcysteine did not prevent CIN in patients at low to moderate risk undergoing cardiac catheterisation with ionic low osmolality contrast medium.
authors.affiliation: Division of Interventional Cardiology, Hospital São Lucas, Pontifícia Universidade Católica-RS, Porto Alegre, Brazil.
authors.forename: V O
authors.initials: VO
authors.lastname: Gomes
authors.forename: C E
authors.initials: CE
authors.lastname: Poli de Figueredo
authors.forename: P
authors.initials: P
authors.lastname: Caramori
authors.forename: R
authors.initials: R
authors.lastname: Lasevitch
authors.forename: L C
authors.initials: LC
authors.lastname: Bodanese
authors.forename: A
authors.initials: A
authors.lastname: Araújo
authors.forename: A P
authors.initials: AP
authors.lastname: Röedel
authors.forename: A P
authors.initials: AP
authors.lastname: Caramori
authors.forename: F S
authors.initials: FS
authors.lastname: Brito
authors.forename: H G
authors.initials: HG
authors.lastname: Bezerra
authors.forename: P
authors.initials: P
authors.lastname: Nery
authors.forename: A
authors.initials: A
authors.lastname: Brizolara
mesh_terms: D000111:Acetylcysteine / Q000008:administration & dosage*; D000284:Administration, Oral; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D006328:Cardiac Catheterization / Q000379:methods*; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography / Q000379:methods; D003404:Creatinine / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007485:Ioxaglic Acid / Q000009:adverse effects*; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration
chemical_list: D003287:Contrast Media; D003404:Creatinine; D000111:Acetylcysteine; D007485:Ioxaglic Acid